Business News | SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
Get latest articles and stories on Business at LatestLY. Lucerne [Switzerland]/New Delhi [India], October 13: The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease. Designed to generate comparative evidence, SPARX aims to address key unanswered clinical questions regarding the safety, efficacy, and long-term outcomes of a "leave nothing behind" treatment…
Read the full report on Latestly
Story file
How this page works. The Headline Update lists this report from Latestly with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.